The $123 Billion Unlock: SpaceX Lockups Begin Expiring as the Mega-IPO Pipeline Tests Market Capacity
The First Real Test of the Mega-IPO Era
SpaceX, which priced the largest IPO in U.S. history on June 11 at $135 per share, is about to face its first structural stress test. Two trading days after the company’s first earnings report — expected August 4 — the first tranche of lockup restrictions begins expiring, freeing roughly 911.5 million insider shares for sale on August 6. A second tranche of approximately 455.8 million shares unlocks around August 20, with additional releases continuing through the one-year anniversary of the IPO. In total, more than 6.4 billion locked-up shares — roughly twelve times the 555.6 million sold at the offering — could eventually enter the public float.[1][2]
The scale is unprecedented. As Matthew Kennedy, senior strategist at Renaissance Capital, notes, the average IPO floats about 20% of its shares to the public. SpaceX floated roughly 5%.[1] That thin float fueled the stock’s initial surge — from $135 at pricing to an intraday high of $225.64 by June 16, a 67% gain in three sessions — before gravity set in. By mid-July, SpaceX had broken below its IPO price, trading as low as $111, a 45% drawdown from the peak.[3][1]
Morningstar analyst Nicolas Owens believes the lockup overhang is already part of the story. “We believe that most of the available shares will come to market, because the existing sellers have low cost basis and long holding periods,” he says. “It’s conceivable that a good deal of the recent slump in SpaceX stock is precisely in anticipation of the dilution from the lockup.”[1]
The Mechanical Double: Forced Buying Meets Forced Selling
The lockup story is not just about supply. It is about the collision of two mechanical forces — insider selling pressure and passive index buying — that together will determine how much of the overhang the market can absorb.
SpaceX’s IPO exposed a deep rift among index providers about how quickly mega-cap newcomers should enter benchmarks:
| Index Provider | Inclusion Rule for SpaceX | Minimum Float | Earliest Entry |
|---|---|---|---|
| S&P Dow Jones (S&P 500) | Unchanged: 12-month seasoning + GAAP profitability | Yes | Mid-2027 at earliest (unprofitable) |
| Nasdaq (Nasdaq-100) | Revised: top-40 market cap fast entry after 15 trading days | None | ~Late June 2026 |
| FTSE Russell (Russell 1000) | Revised: relaxed 5% float minimum | Reduced | September or December 2026 reconstitution |
| MSCI | Existing: 10-trading-day rule (since 2007) | Standard | ~Late June 2026 |
| CRSP | Existing: fast-track after 5 trading days | Standard | ~Late June 2026 |
Nasdaq’s revised methodology means SpaceX could enter the Nasdaq-100 at an estimated 0.47%–0.70% initial weight. Goldman Sachs estimates that inclusion alone could trigger as much as $60 billion in forced buying across the Nasdaq-100 tracking ecosystem.[3] Bloomberg Intelligence puts the combined Nasdaq-100 and Russell 1000 passive demand at roughly 24% of SpaceX’s public float, with a subsequent S&P 500 inclusion — whenever profitability allows — adding demand for another 19%.[3]
But here is the structural wrinkle: index funds run at cash balances below 1% of assets. When SpaceX is added, the required purchases are funded by proportional trimming of every other constituent in the index. Crestwood Advisors estimates that if the Nasdaq-100 tracking ecosystem needs to allocate approximately $7 billion to SpaceX at inclusion, that same $7 billion becomes proportional selling pressure distributed across the other 100 names — roughly $70 million per constituent. For the largest names, that is a rounding error. For smaller constituents, it is more meaningful.[3]
The Tesla precedent is instructive. When Tesla was added to the S&P 500 on December 21, 2020, passive funds needed to buy an estimated $50–$80 billion of shares. On the last trading day before inclusion, over 200 million shares traded, including roughly 69 million shares worth approximately $50 billion in the closing auction alone. The stock had risen roughly 70% in the five weeks between S&P’s announcement and the effective date, reflecting front-running by active investors positioning ahead of the forced buying.[3]
Owens at Morningstar is skeptical that index demand alone will offset the lockup supply. “Unless something changes the fundamental story or sentiment — like for the better — the supply from these lockups will outweigh demand even from index funds,” he says.[1]
A Cooling IPO Market Underneath the Mega-Caps
While SpaceX dominates headlines, the broader IPO market is sending a more cautious signal. Several recent deals have struggled:
| Ticker | Company | Pricing | Deal Size | Return from IPO (as of Jul 24) |
|---|---|---|---|---|
| CSQR | Csquare (data centers) | $21, below $23–$27 range | $1.05B | -0.5%[4] |
| STDN | Standard Nuclear (nuclear fuel) | Slashed offering size | $150M | -40.6%[4] |
| QMLS | QumulusAI (AI cloud, direct listing) | Direct listing | — | -47.9%[4] |
| SCTX | Scribe Therapeutics (CRISPR biotech) | $15, high end, upsized | $128.7M | Just priced Jul 24[4] |
Csquare, a Brookfield-backed data center operator with 64 facilities across the U.S. and U.K., priced below its range and closed 1.57% lower in its NYSE debut.[5] Standard Nuclear slashed its offering size by roughly half and still fell about 10% on its first day.[5] QumulusAI, which chose an unusual direct listing route, plunged 33% on its second day of trading despite announcing an Nvidia partnership.[5]
Renaissance Capital’s recap described both Csquare and Standard Nuclear as “underwhelming amid a cautious market.”[5] When AI-infrastructure and next-generation nuclear fuel — two of the hottest thematic categories — struggle to find a bid, it suggests that investor appetite for new issuance has thinned even as the mega-cap pipeline remains enormous.
The Pipeline Behind SpaceX
The supply test extends well beyond SpaceX’s lockup. Three of the largest IPO candidates in history have filed confidential S-1 registrations:
- Anthropic filed draft IPO paperwork on June 1, 2026, at a reported $965 billion valuation.[6]
- OpenAI filed confidentially on June 8, 2026, at a reported $852 billion valuation.[6]
- SpaceX has already listed, priced at a $1.77 trillion valuation.[3]
Polymarket traders currently favor Anthropic at 87% to IPO before OpenAI, pricing Anthropic at 76% to list by year-end 2026. SpaceX carries 88% odds of being 2026’s largest IPO by market cap.[6] PitchBook has flagged a real possibility that OpenAI could delay to 2027, which would stagger the supply timeline but leave the aggregate issuance intact.[6]
Beyond the AI trio, names like Databricks, Stripe, Anduril, Plaid, and Canva are widely expected to follow.[6] Paul Comstock Partners estimates that SpaceX, Anthropic, and OpenAI alone comprise over $3 trillion in combined estimated value — an influx that will reshape equity benchmarks.[7]
What the Academic Record Says About Lockup Expirations
The lockup effect is not a Wall Street anecdote — it is a documented statistical pattern. The seminal Field and Hanka (2001) study, covering 2,529 firms from 1988 to 1997, found a statistically significant negative abnormal return of approximately 1.5% in the trading days surrounding lockup expiration, concentrated in venture-backed technology firms.[3]
Crestwood’s analysis of 25 U.S. mega IPOs from 2011 to 2021 found that the median newly listed stock trades below its IPO price for much of its first two years. SpaceX’s path — a sharp initial spike followed by a swift reversion — is tracking the empirical pattern, not defying it.[3] Renaissance Capital data shows 30-day post-IPO volatility running 45–50% higher than seasoned stocks in the same market. Perhaps most strikingly, 41% of 2023 IPOs delisted within five years, with 29% attributed to poor performance.[3]
What to Watch Next
- August 4: SpaceX’s first earnings report as a public company. The numbers will frame the narrative heading into the first lockup release.
- August 6: First lockup tranche expires — approximately 911.5 million shares become eligible for sale.[2]
- August 20: Second tranche expires — approximately 455.8 million additional shares unlock.[1]
- September–December 2026: Additional lockup tranches expire; FTSE Russell reconstitution could trigger SpaceX’s entry into the Russell 1000.[3]
- Late 2026: Anthropic’s potential public listing — if it prices, it will be the second-largest IPO candidate behind SpaceX and the first direct test of whether the market can absorb multiple mega-cap newcomers simultaneously.
- Mid-2027: Earliest possible S&P 500 eligibility for SpaceX, contingent on achieving GAAP profitability. S&P’s refusal to bend its rules means the largest single wave of forced buying remains months away.[3]
The question is not whether SpaceX’s lockup will release supply — it will, on a schedule and a scale the IPO market has never processed before. The question is whether index-fund demand and organic buyer interest can absorb that supply without the stock’s already-elevated volatility breaking further. The early read from the broader IPO market — where data center, nuclear fuel, and AI cloud deals are all trading underwater — is not reassuring. Watch the August 6 volume and the first-week post-lockup price action. If the float triples by late September and the stock holds its range, the market passed the test. If it does not, the pipeline behind SpaceX may price into a very different wind.
Sources
- Why SpaceX’s Earnings Will Likely Be Followed by a Wave of Stock Sales | Morningstar
- SpaceX falls under IPO price, as lockup expirations loom
- July 2026 Economic and Market Update: The Mega-IPO Era Arrives - Crestwood Advisors
- SCTX IPO News - Cardiovascular disease biotech Scribe Therapeutics prices upsized IPO at…
- IPO News - US IPO Weekly Recap: Csquare and Standard Nuclear both underwhelm amid cautiou…
- AI IPO Tracker 2026: SpaceX, OpenAI, Anthropic, Databricks
- Why SpaceX’s Earnings Will Likely Be Followed by a Wave of Stock Sales